Navigation Links
Epizyme identifies novel opportunity for treatment of genetically defined human B-cell lymphomas
Date:11/15/2010

Cambridge, MA, November 15, 2010 - Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, today announced the publication of breakthrough new research in the Proceedings of the National Academy of Sciences (USA). The discovery, centered on the epigenetic enzyme EZH2, illuminates a clear path for the translation of basic science into targeted therapies for the safe and effective treatment of specific forms of human lymphomas. EZH2 is a histone methyltransferase (HMT), a class of enzymes that play an important role in regulating the activity of particular groups of genes that are involved in serious diseases, including cancer.

The paper describes how the development of two non-Hodgkin lymphomas - follicular lymphoma and germinal center B-cell like subtype of diffuse large B-cell lymphoma - requires the combined activities of both the wild-type and Tyr641 mutants of EZH2. This novel insight reinforces the development of targeted therapeutics for these patients, as it repudiates the previous supposition that the Tyr641 mutation resulted in a loss of EZH2 function.

Dr. Robert A. Copeland, EVP of R&D and CSO, said, "We believe this is the first example of a human disease that is reliant on the combined catalytic activity of both normal and disease-associated mutant enzymes. By targeting HMTs with clear genetic disease associations, such as EZH2, Epizyme takes a hypothesis-driven approach to development of personalized therapeutics for specific patient populations with high unmet needs. Our product platform enables the creation of novel, potent and selective small molecule HMT inhibitors."

"This paper is a novel, important and representative example of the rapidly growing understanding of the oncogenic role played by HMTs in many cancers. It highlights the promise of HMT inhibitors as novel therapeutics against these targets," said Professor Christopher T. Walsh, the Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology (BCMP) at Harvard Medical School and a member of Epizyme's Scientific Advisory Board.


'/>"/>

Contact: Jennifer Conrad
jconrad@macbiocom.com
781-235-3060
MacDougall Biomedical Communications, Inc.
Source:Eurekalert

Related biology technology :

1. Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV
2. New Industry Research Identifies "Operational Gap" in Clinical Trial Portfolio Management
3. DNA2.0 Unlocks The Secrets Of Optimized Gene Design: Company Identifies Codon Choice Design Principles for Optimal Protein Expression
4. ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
5. Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning
6. New research identifies faster detection of viruses
7. Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force
8. Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack
9. Oligomerix, Inc. Awarded Phase II NIH Grant to Discover Novel Drugs for Alzheimers Disease
10. Novel metamaterial vastly improves quality of ultrasound imaging
11. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):